Monte Rosa Therapeutics

(NASDAQ) GLUE

Current Price$19.07

Market Cap$1.54B

Since IPO (2021)-9%

5 YearN/A

1 Year+284%

1 Month+24%

Monte Rosa Therapeutics Financials at a Glance

Market Cap

$1.54B

Revenue (TTM)

$123.67M

Net Income (TTM)

$38.63M

EPS (TTM)

$-0.62

P/E Ratio

-31.26

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$19.07

Volume

713,387.533

Open

$19.16

Price

$19.07

Volume

713,387.533

Open

$19.16

Previous Close

$19.01

Daily Range

$18.68 - $19.85

52-Week Range

$3.51 - $25.77

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$19.07

Volume

713,387.533

Open

$19.16

Previous Close

$19.01

Daily Range

$18.68 - $19.85

52-Week Range

$3.51 - $25.77

GLUE News

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise

Jonathan PoncianoApr 21, 2026

Monte Rosa (GLUE) Q2 Revenue Jumps 394%

Motley Fool Markets TeamAug 7, 2025

GLUE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Monte Rosa Therapeutics

Industry

Biotechnology

Sector

Health Care

Employees

150

CEO

Markus Warmuth, MD

Website

www.monterosatx.com

Headquarters

Boston, MA 02210, US

GLUE Financials

Key Financial Metrics (TTM)

Gross Margin

97%

Operating Margin

-44%

Net Income Margin

-31%

Return on Equity

-17%

Return on Capital

-14%

Return on Assets

-9%

Earnings Yield

-3.20%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.54B

Shares Outstanding

80.02M

Volume

713.39K

Avg. Volume

1.09M

Financials (TTM)

Gross Profit

$115.32M

Operating Income

$54.21M

EBITDA

$45.85M

Operating Cash Flow

$22.80M

Capital Expenditure

$4.70M

Free Cash Flow

$27.50M

Cash & ST Invst.

$377.10M

Total Debt

$39.19M

Monte Rosa Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q4 2025YOY CHG

Revenue

$2.78M

-95.4%

Gross Profit

$693.00K

-98.9%

Gross Margin

24.92%

N/A

Market Cap

$1.54B

N/A

Market Cap/Employee

$10.87M

N/A

Employees

142

N/A

Net Income

$46.13M

-443.3%

EBITDA

$47.63M

-416.1%

Quarterly Fundamentals

Name

Q4 2025YOY CHG

Net Cash

$337.91M

+2.6%

Accounts Receivable

$4.60M

+2559.0%

Inventory

$0.00

N/A

Long Term Debt

$34.79M

-10.8%

Short Term Debt

$4.40M

+18.4%

Return on Assets

-8.61%

N/A

Return on Invested Capital

-14.10%

N/A

Free Cash Flow

$43.78M

-134.0%

Operating Cash Flow

$43.01M

-133.4%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

VIRVir Biotechnology, Inc.

VIRVir Biotechnology, Inc.$10.28-3.38%

AVBPArriVent BioPharma, Inc. Common Stock

AVBPArriVent BioPharma, Inc. Common Stock$30.04-0.96%

GERNGeron Corporation

GERNGeron Corporation$1.51-1.31%

TBPHTheravance Biopharma, Inc.

TBPHTheravance Biopharma, Inc.$16.76-0.30%

DAWNDay One Biopharmaceuticals, Inc.

DAWNDay One Biopharmaceuticals, Inc.$21.53+0.00%

MGTXMeiraGTx Holdings plc

MGTXMeiraGTx Holdings plc$9.08-0.55%

ARVNArvinas, Inc.

ARVNArvinas, Inc.$10.22-0.68%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$84.52-0.01%

NOKNokia

NOKNokia$11.30+0.05%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$60.74-0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$12.14-0.01%

SOFISoFi Technologies

SOFISoFi Technologies$18.36-0.02%

RIGTransocean

RIGTransocean$6.79+0.04%

ERASErasca

ERASErasca$9.90-0.48%

Questions About GLUE

What is the current price of Monte Rosa Therapeutics?

Monte Rosa Therapeutics is trading at $19.01 per share.

What is the 52-week range for Monte Rosa Therapeutics?

Over the past 52 weeks, Monte Rosa Therapeutics has traded between $3.51 and $25.77.

How much debt does Monte Rosa Therapeutics have?

As of the most recent reporting period, Monte Rosa Therapeutics reported total debt of $39.19M.

How much cash does Monte Rosa Therapeutics have on hand?

Monte Rosa Therapeutics reported $129.88M in cash and cash equivalents in its most recent financial results.

What is Monte Rosa Therapeutics’s dividend yield?

Monte Rosa Therapeutics does not currently have a dividend yield.

Monte Rosa Therapeutics

Monte Rosa Therapeutics Financials at a Glance

GLUE News

Monte Rosa CEO Sells $141K in Stock Amid 300% Surge and Recent Capital Raise

Monte Rosa (GLUE) Q2 Revenue Jumps 394%

GLUE: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Monte Rosa Therapeutics

GLUE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Monte Rosa Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About GLUE

What is the current price of Monte Rosa Therapeutics?

What is the 52-week range for Monte Rosa Therapeutics?

How much debt does Monte Rosa Therapeutics have?

How much cash does Monte Rosa Therapeutics have on hand?

What is Monte Rosa Therapeutics’s dividend yield?

Premium Investing Services